Pharming Group NV
AEX:PHARM

Watchlist Manager
Pharming Group NV Logo
Pharming Group NV
AEX:PHARM
Watchlist
Price: 0.8735 EUR -0.8%
Market Cap: 592.5m EUR
Have any thoughts about
Pharming Group NV?
Write Note

Pharming Group NV
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Pharming Group NV
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Pharming Group NV
AEX:PHARM
Long-Term Debt
$119.9m
CAGR 3-Years
-5%
CAGR 5-Years
38%
CAGR 10-Years
60%
ProQR Therapeutics NV
NASDAQ:PRQR
Long-Term Debt
€11.5m
CAGR 3-Years
-29%
CAGR 5-Years
2%
CAGR 10-Years
N/A
Uniqure NV
NASDAQ:QURE
Long-Term Debt
$477.8m
CAGR 3-Years
88%
CAGR 5-Years
68%
CAGR 10-Years
37%
argenx SE
XBRU:ARGX
Long-Term Debt
$28.1m
CAGR 3-Years
85%
CAGR 5-Years
50%
CAGR 10-Years
N/A
Merus NV
NASDAQ:MRUS
Long-Term Debt
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
LAVA Therapeutics NV
NASDAQ:LVTX
Long-Term Debt
$591k
CAGR 3-Years
-47%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Pharming Group NV
Glance View

Market Cap
592.7m EUR
Industry
Biotechnology

Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company is headquartered in Leiden, Zuid-Holland and currently employs 321 full-time employees. The firm is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The firm's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.

PHARM Intrinsic Value
1.2014 EUR
Undervaluation 27%
Intrinsic Value
Price

See Also

What is Pharming Group NV's Long-Term Debt?
Long-Term Debt
119.9m USD

Based on the financial report for Sep 30, 2024, Pharming Group NV's Long-Term Debt amounts to 119.9m USD.

What is Pharming Group NV's Long-Term Debt growth rate?
Long-Term Debt CAGR 10Y
60%

Over the last year, the Long-Term Debt growth was -24%. The average annual Long-Term Debt growth rates for Pharming Group NV have been -5% over the past three years , 38% over the past five years , and 60% over the past ten years .

Back to Top